Creatine monohydrate in DM2/PROMM: a double-blind placebo-controlled clinical study. Proximal myotonic myopathy

Neurology. 2003 Feb 11;60(3):500-2. doi: 10.1212/01.wnl.0000044405.29988.e1.


The efficacy and safety of creatine monohydrate (Cr) in patients with myotonic dystrophy type 2/proximal myotonic myopathy were studied in a small placebo-controlled double-blind trial. Twenty patients received either Cr or placebo for 3 months. After 3 months, there were no significant differences of muscle strength as assessed by hand-held dynamometry, testing of maximum grip strength, Medical Research Council scoring, and the Neuromuscular Symptom Score between the two groups. Some measures indicated trends toward mild improvement with Cr. Myalgia improved in two patients.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Creatine / adverse effects
  • Creatine / analogs & derivatives*
  • Creatine / therapeutic use*
  • Dietary Supplements
  • Double-Blind Method
  • Female
  • Hand Strength
  • Humans
  • Male
  • Middle Aged
  • Muscle Weakness / diagnosis
  • Muscle Weakness / drug therapy
  • Muscle Weakness / etiology
  • Myotonic Disorders / complications
  • Myotonic Disorders / drug therapy*
  • Myotonic Disorders / genetics
  • Pilot Projects
  • Treatment Outcome


  • Creatine